Clinical Trials
12 trialsNCT07431216 2026-03-30
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Starlight Therapeutics Inc.
Phase 1/2 Not yet recruiting
NCT06208657 2026-01-28
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2 Recruiting
NCT07364422 2026-01-23
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Onconic Therapeutics Inc.
Phase 1/2 Not yet recruiting
NCT07334301 2026-01-12
BEACON2
University of Birmingham
Phase 1/2 Recruiting
NCT00302744 2025-03-13
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase 1/2 Completed
NCT04138381 2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Unknown
NCT03076437 2021-03-19
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Institute for Innovation and Translational Medicine
Phase 1/2 Completed
NCT03191773 2017-06-20
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2 Unknown
NCT00095706 2015-09-25
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Translational Oncology Research International
Phase 1/2 Completed
NCT01711398 2015-02-12
IP N02
Elro Pharma
Phase 1/2 Completed
NCT01027676 2013-11-14
Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)
National Cancer Center, Korea
Phase 1/2 Unknown
NCT00087854 2008-04-23
Study of Individualized Amonafide to Treat Prostate Cancer
Xanthus Pharmaceuticals, Inc.
Phase 1/2 Completed